Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
SurModics Inc is a medical devices business based in the US. SurModics shares (SRDX) are listed on the NASDAQ and all prices are listed in US Dollars. SurModics employs 389 staff and has a trailing 12-month revenue of around $97.9 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $30.40 |
|---|---|
| 52-week range | $28.28 - $58.95 |
| 50-day moving average | $33.67 |
| 200-day moving average | $39.39 |
| Wall St. target price | $74.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.76 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $30.4 from 2022-09-30
| 1 week (2022-09-22) | N/A |
|---|---|
| 1 month (2022-08-31) | -9.77% |
| 3 months (2022-07-01) | -19.62% |
| 6 months (2022-04-01) | -31.81% |
| 1 year (2021-10-01) | -46.27% |
|---|---|
| 2 years (2020-10-02) | -23.96% |
| 3 years (2019-10-03) | 43.92 |
| 5 years (2017-10-03) | 32.6 |
Valuing SurModics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of SurModics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
SurModics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.8952. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into SurModics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $97.9 million |
|---|---|
| Gross profit TTM | $38.5 million |
| Return on assets TTM | -6.72% |
| Return on equity TTM | -9.65% |
| Profit margin | -13.11% |
| Book value | $8.94 |
| Market capitalisation | $425.8 million |
TTM: trailing 12 months
We're not expecting SurModics to pay a dividend over the next 12 months.
SurModics's shares were split on a 2:1 basis on 6 December 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your SurModics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for SurModics shares which in turn could have impacted SurModics's share price.
Over the last 12 months, SurModics's shares have ranged in value from as little as $28.28 up to $58.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SurModics's is 0.9577. This would suggest that SurModics's shares are less volatile than average (for this exchange).
Surmodics, Inc. , together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.